UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
Joshua Dawson House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|
Form 20-F
|
☒
|
Form 40-F
|
GH Research PLC announces the presentation of posters related to its GH001-TRD-201 and GH001-BD-202 clinical trials at the 64th American College of Neuropsychopharmacology (ACNP) annual
meeting (the “Congress”), which is scheduled to take place from January 12-15, 2026, in Paradise Island, Bahamas.
A copy of the poster to be presented by Sanjay J. Mathew during the Congress is attached hereto as Exhibit 99.1.
A copy of the poster to be presented by Lisa Harding during the Congress is attached hereto as Exhibit 99.2.
A copy of the poster to be presented by Andreas Reif during the Congress is attached hereto as Exhibit 99.3.
1
EXHIBIT INDEX
|
Poster to be presented by Sanjay J. Mathew with Title: Suicidal Ideation and Behavior in Patients with Treatment-Resistant Depression Treated with GH001
|
|
|
Poster to be presented by Lisa Harding with Title: Rapid Antidepressant Effects of Inhaled GH001 in Treatment-Resistant Depression: Results from a Phase 2b,
Double-Blind, Randomized Controlled Trial with 6-Month Follow-Up
|
|
|
Poster to be presented by Andreas Reif with Title: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a
Current Major Depressive Episode
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
GH Research PLC
|
||
|
Date: January 8, 2025
|
||
|
By:
|
/s/ Julie Ryan
|
|
|
Name:
|
Julie Ryan
|
|
|
Title:
|
Vice President, Finance
|
|
3